Clinical study of Jianpi Yanggan Decoction combined with Tongluo Yanggan application in the treatment of autoimmune hepatitis

Phase 1

Recruiting

• Conditions: Autoimmune Hepatitis

• Registration Number: ITMCTR2022000094
• Lead Sponsor: Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria for autoimmune hepatitis;
2. Meet the diagnostic criteria of Ganyu and PiXu;
3. The age is between 18-65 years old, and the gender is not limited;
4. Willing to participate in this research and sign the informed consent.

Exclusion Criteria

1. Patients with liver damage caused by other reasons (such as viral, drug, alcoholic and non-alcoholic fatty liver disease, etc.);
2. Those with acute severe complications, those with critical illnesses such as liver cirrhosis, decompensated hepatic encephalopathy, and liver failure;
3. Pregnant or lactating women, those with allergic constitution;
4. Patients with mental disorders who cannot cooperate with this study;
5. Patients with severe heart, brain, lung, kidney, hematopoietic, immune and other system diseases;
6. Other conditions deemed inappropriate by the researcher.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
liver function;Immunoglobulin;

Secondary Outcome Measures

Name	Time	Method
VAS;TCM symptoms;LSM;FFS;liver ultrasound;